MedTech Dive December 22, 2025
MiniMed is pitching the breadth of its portfolio as an advantage over more focused rivals such as Dexcom and Insulet.
Dive Brief:
- Medtronic’s planned diabetes device spinoff MiniMed has filed for an initial public offering, the company said Friday.
- The filing shows MiniMed made a $198 million loss on sales of $2.72 billion in its 2025 fiscal year. MiniMed plans to grow profits by using its broad portfolio, which features both insulin pumps and glucose sensors, to generate more revenue per customer than its competitors.
- MiniMed’s Simplera CGM sensor is key to the strategy, but the company warned it may be unable to make the continuous glucose monitor profitably amid manufacturing challenges.
Dive Insight:
Medtronic announced in...
Today's Sponsors
Today's Sponsor